Recent corporate updates from Codexis feature positive financial results for the second quarter, highlighted by $14.9 million in revenue and robust product gross margins reaching 73 percent. Management successfully closed a strategic equity financing round yielding $25 million in net proceeds, extending the company's projected cash operational runway through 2028. Additionally, Codexis is actively advancing its proprietary ECO Synthesis technology platform, reporting strong progress on stereochemistry control for therapeutic oligonucleotides and moving forward with plans to construct an advanced Good Manufacturing Practice production facility to support future commercial-scale manufacturing demands.